Skip to main content

Table 1 Summary of baseline demographic and disease characteristics (ITT population)

From: Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

  Asian patients Non-Asian patients
  Pazopanib
(n = 188)
Sunitinib
(n = 179)
Pazopanib
(n = 349)
Sunitinib
(n = 358)
Age, median years (range) 59.0 (18–81) 58.0 (23–82) 62.0 (35–88) 63.0 (33–86)
Male sex, n (%) 137 (73) 137 (77) 247 (71) 265 (74)
Race, n (%)
 Asian—Central/South Asian heritage 2 (1) 1 (< 1) 0 0
 Asian—East Asian heritage 154 (82) 144 (80) 0 0
 Asian—Japanese heritage 29 (15) 31 (17) 0 0
 Asian—South East Asian heritage 3 (2) 3 (2) 0 0
 Non-Asian—White/Caucasian/European heritage 0 0 346 (99) 356 (99)
 Non-Asian—Arabic/North African heritage 0 0 2 (< 1) 2 (< 1)
 Non-Asian—mixed race 0 0 1 (< 1) 0
Time since initial diagnosis, median days (range) 93.5 (1–6039) 145.5 (2–6239) 287.0 (10–9117) 252.0 (9–7922)
Histology, n (%)
 Clear cell 183 (97) 165 (92) 322 (92) 331 (92)
 Predominantly clear cell 5 (3) 10 (6) 20 (6) 20 (6)
 Other 0 4 (2) 7 (2) 6 (2)
 Missing 0 0 0 1 (< 1)
Karnofsky performance scale, n (%)
 70 or 80 37 (20) 20 (11) 96 (28) 103 (29)
 90 or 100 151 (80) 159 (89) 253 (72) 255 (71)
Prior nephrectomy, n (%) 152 (81) 152 (85) 292 (84) 300 (84)
Baseline levels of LDH, n (%)
 > 1.5 × ULN 10 (5) 6 (3) 28 (8) 22 (6)
 ≤ 1.5 × ULN 178 (95) 173 (97) 321 (92) 336 (94)
Number of organs involved, n (%)
 1 53 (28) 50 (28) 61 (17) 54 (15)
 2 71 (38) 67 (37) 127 (36) 131 (37)
 ≥ 3 63 (34) 62 (35) 161 (46) 173 (48)
 Missing 1 (< 1) 0 0 0
Location of disease at baseline, n (%)
 Lung 146 (78) 143 (80) 262 (75) 270 (75)
 Lymph nodes 62 (33) 68 (38) 153 (44) 172 (48)
 Kidney 57 (30) 43 (24) 101 (29) 105 (29)
 Bone 36 (19) 33 (18) 65 (19) 49 (14)
 Other 27 (14) 27 (15) 45 (13) 50 (14)
 Liver 24 (13) 30 (17) 60 (17) 78 (22)
MSKCC risk category, n (%)
 Favorable risk 47 (25) 55 (31) 97 (28) 90 (25)
 Intermediate risk 119 (63) 112 (63) 192 (55) 209 (58)
 Poor risk 18 (10) 9 (5) 48 (14) 41 (11)
 Unknown 4 (2) 3 (2) 12 (3) 18 (5)
Heng risk category, n (%)
 Favorable risk 43 (23) 50 (28) 92 (26) 82 (23)
 Intermediate risk 112 (60) 98 (55) 177 (51) 203 (57)
 Poor risk 30 (16) 27 (15) 74 (21) 63 (18)
 Unknown 3 (2) 4 (2) 6 (2) 10 (3)
Number of metastatic sites, n (%)
 0 1 (< 1) 3 (2) 2 (< 1) 2 (< 1)
 1 77 (41) 57 (32) 91 (26) 77 (22)
 2 58 (31) 72 (40) 130 (37) 146 (41)
 ≥ 3 51 (27) 47 (26) 126 (36) 133 (37)
 Missing 1 (< 1) 0 0 0
  1. ITT intent-to-treat, LDH lactate dehydrogenase, MSKCC Memorial Sloan Kettering Cancer Center, ULN upper limit of normal